Want to see JP:4538 full AI Analyst Report?
Fuso Pharmaceutical Industries,Ltd. (4538) AI Stock Analysis
Fuso Pharmaceutical Industries,Ltd.
(TSE/TYO:4538)
The overall score of 62 reflects a mixed picture. Financial performance is the primary drag, with concerning cash flow and rising leverage offsetting modest revenue growth. However, technical indicators suggest bullish momentum, and valuation appears attractive with a low P/E and solid dividend yield. Investors should weigh the near-term positive signals against the underlying financial risks.
Fuso Pharmaceutical Industries,Ltd. (4538) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 17.99B
- Dividend Yield
- 4.27%
- Average Volume (3M)
- 18.82K
- Price to Earnings (P/E)
- 8.2
- Beta (1Y)
- 0.56
- Revenue Growth
- 2.29%
- EPS Growth
- ―
- Country
- Japan
- Employees
- 1,370
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Fuso Pharmaceutical Industries,Ltd. Business Overview & Revenue Model
Company Description
Fuso Pharmaceutical Industries, Ltd. is a Japanese firm primarily involved in the development and commercialization of pharmaceutical goods. Their product range encompasses prescription medications, particularly injectables and solutions for artifici...
How the Company Makes Money
Fuso Pharmaceutical Industries makes money primarily by selling prescription pharmaceutical products in Japan. Its revenue model is centered on (1) product sales of medical-use drugs—especially hospital-oriented formulations such as injectables—suppl...
Fuso Pharmaceutical Industries,Ltd. Financial Statement Overview
Summary
Fuso Pharmaceutical shows modest revenue growth but thin profitability (Income Statement score 48). Leverage has increased significantly (Balance Sheet score 35) and operating cash flow is negative, with free cash flow deeply negative for three years (Cash Flow score 12). This raises liquidity concerns and indicates below-average financial health.
Income Statement
48NeutralBalance Sheet
35NegativeCash Flow
12Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 62.85B | 62.31B | 60.56B | 55.41B | 51.02B | 49.63B |
| Gross Profit | 16.11B | 15.99B | 16.19B | 13.52B | 13.36B | 12.91B |
| EBITDA | 5.50B | 5.38B | -2.98B | 3.67B | 4.63B | 4.47B |
| Net Income | 2.19B | 2.01B | -3.29B | 1.38B | 1.60B | 1.48B |
Balance Sheet | ||||||
| Total Assets | 87.47B | 90.32B | 82.52B | 76.46B | 72.81B | 69.66B |
| Cash, Cash Equivalents and Short-Term Investments | 4.57B | 4.85B | 6.26B | 5.12B | 8.01B | 7.35B |
| Total Debt | 26.31B | 28.46B | 21.29B | 12.72B | 11.41B | 12.09B |
| Total Liabilities | 51.72B | 55.26B | 49.48B | 39.79B | 37.15B | 35.12B |
| Stockholders Equity | 35.75B | 35.06B | 33.04B | 36.66B | 35.65B | 34.53B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -7.49B | -5.43B | -2.62B | 1.32B | 2.20B |
| Operating Cash Flow | 0 | -6.22B | -3.31B | 627.00M | 2.87B | 3.61B |
| Investing Cash Flow | 0 | -1.51B | -3.17B | -3.54B | -1.39B | -1.66B |
| Financing Cash Flow | 0 | 6.32B | 7.62B | 14.00M | -813.00M | -1.67B |
Fuso Pharmaceutical Industries,Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4538, the sentiment is Negative. The current price of 2108.00 is below the 20-day moving average (MA) of 2120.50, below the 50-day MA of 2180.29, and below the 200-day MA of 2183.18, indicating a bearish trend. The MACD of -21.11 indicates Negative momentum. The RSI at 41.63 is Neutral, neither overbought nor oversold. The STOCH value of 41.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4538.
Fuso Pharmaceutical Industries,Ltd. Peers Comparison
Overall Rating
JP:452481.5Outperform- JP:453862Neutral
JP:457461Neutral
JP:292959Neutral
JP:453946.5Neutral
JP:451245Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4524 | 82Outperform | JPY 8.95B | 11.40 | ― | 2.96% | 0.98% | 69.36% |
| JP:4538 | 62Neutral | JPY 18.48B | 8.21 | ― | 4.27% | 2.29% | ― |
| JP:4574 | 61Neutral | JPY 13.02B | 18.99 | ― | 1.27% | 13.30% | 66.38% |
| JP:2929 | 59Neutral | JPY 18.40B | 9.29 | ― | 3.46% | -3.12% | 406.78% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| JP:4539 | 47Neutral | JPY 5.47B | -44.12 | ― | 3.30% | 0.31% | -194.72% |
| JP:4512 | 45Neutral | JPY 10.52B | 30.73 | ― | 1.16% | 25.89% | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4538 | Fuso Pharmaceutical Industries,Ltd. | 2107.00 | 63.79 | 3.12% | |
| JP:2929 | Pharma Foods International Co., Ltd. | 635.00 | -147.04 | -18.80% | |
| JP:4512 | Wakamoto Pharmaceutical Co., Ltd. | 303.00 | 15.42 | 5.36% | |
| JP:4524 | Morishita Jintan Co., Ltd. | 2195.00 | 138.01 | 6.71% | |
| JP:4539 | Nippon Chemiphar Co., Ltd. | 1515.00 | 30.29 | 2.04% | |
| JP:4574 | Taiko Pharmaceutical Co., Ltd. | 260.00 | -15.00 | -5.45% |
Fuso Pharmaceutical Industries,Ltd. Corporate Events
Fuso Pharmaceutical Delivers Strong Q1 Profit Jump but Keeps Cautious Full-Year Outlook
Fuso Pharmaceutical Industries reported solid first-quarter non-consolidated results for the three months ended June 30, 2026, with net sales up 3.5% year-on-year to ¥16,046 million and operating profit surging 63.0% to ¥972 million, liftin...
Fuso Pharmaceutical Profit Falls Despite Higher Sales as Dividend Rises
Fuso Pharmaceutical reported a 2.9% rise in net sales to ¥62.3 billion for the year ended March 31, 2026, but saw operating profit drop 36.1% to ¥2.64 billion and ordinary profit fall 37.9% to ¥2.35 billion, even as it swung from a los...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 17, 2026